Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFrench, Janine-
dc.contributor.authorLocarnini, Stephen-
dc.contributor.authorZoulim, Fabien-
dc.identifier.citationCurrent opinion in HIV and AIDS 2020; 15(3): 165-172-
dc.description.abstractThe current aim in the HBV landscape is to develop therapeutic strategies to achieve a functional cure of infection, characterized by a sustained loss of HBsAg off-treatment. Current treatment options, that is, nucleos(t)ide analogues and IFN are effective at viral suppression but very poor at achieving HBsAg loss. This article is designed to summarize the HBV life cycle in order to review the current treatment strategies and compounds targeting different points of the virus life cycle, which are either in preclinical or clinical phases. Recently our developed understanding of the HBV life cycle has enabled the development of multiple novel treatment options, all aiming for functional cure. It is likely that combinations of novel treatments will be needed to achieve a functional cure, including those that target the virus itself as well as those that target the immune system.-
dc.titleDirect-acting antivirals and viral RNA targeting for hepatitis B cure.-
dc.typeJournal Article-
dc.identifier.journaltitleCurrent opinion in HIV and AIDS-
dc.identifier.affiliationVictorian Infectious Diseases Laboratory, Victoria, Australiaen
dc.identifier.affiliationINSERM U1052- Cancer Research Center of Lyon (CRCL), 69008 Lyon, Franceen
dc.identifier.affiliationVictorian Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Hepatology, Hôpital de la Croix Rousse, Hospices Civils de Lyonen
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.